Canakinumab for the Treatment of Postprandial Hypoglycemia

Summary

The primary objective of this randomized trial is to test whether a treatment with canakinumab is superior to placebo in patients with postprandial hypoglycemia after bariatric surgery, that is if it improves health related quality of life (mentally or physically) or reduces the risk of hypoglycemic events.

Timeline

Start

2023-04-17

Primary completion

2026-05-31

Completion

2026-05-31

Drugs

Indications